Answers are grounded in this paper and cite their sources.
Covalent RNA conjugates have proved effective in basic research and therapy, yet their broader use is limited by synthetic complexity and high costs. Here, we describe a modular, redox-responsive strategy for late-stage conjugation of diverse biofunctional ligands onto RNA. We show that acylation of RNA 2′-OH groups with disulfide-containing acyl moieties enables thiol–disulfide exchange with thiol-bearing ligands, including N-acetylgalactosamine (GalNAc), peptides, biotin, and captopril. The resulting conjugates undergo deconjugation under reducing conditions, tracelessly regenerating native RNA and enabling recovery of RNA function. The multivalent RNA-GalNAc construct displays preferential uptake in asialoglycoprotein receptor (ASGPR)-rich cells. Installation of biotin followed by streptavidin complexation yields bulky biotinylated RNA–streptavidin complexes that shield nuclease-sensitive RNA regions and markedly enhance the nuclease resistance of both short synthetic RNA and long messenger mRNA (mRNA). This platform may expand the chemical toolbox for RNA conjugation and support the development of functionally diverse RNA conjugates.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: